{
    "clinical_study": {
        "@rank": "85686", 
        "arm_group": [
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE 9-11UM", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE 9-11UM WITH SLS", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 20UM", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 20UM WITH SLS", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 5UM", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 5UM WITH SLS", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effects of varying particle size on the\n      pharmacokinetics of PH-797804"
        }, 
        "brief_title": "A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects and/or healthy female subjects of non-child bearing potential\n             between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically\n             relevant abnormalities identified by a detailed medical history, full physical\n             examination, including blood pressure and pulse rate measurements, 12-lead ECG and\n             clinical laboratory tests.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110\n             lbs).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  A positive urine drug screen.\n\n          -  History of regular alcohol consumption exceeding 14 drinks/week for males."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924650", 
            "org_study_id": "A6631040"
        }, 
        "intervention": [
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE 9-11UM", 
                "description": "Tablet, 6 mg, single dose", 
                "intervention_name": "PH-797804", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE 9-11UM WITH SLS", 
                "description": "Tablet, 6 mg, single dose", 
                "intervention_name": "PH-797804", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 20UM", 
                "description": "Tablet, 6 mg, single dose", 
                "intervention_name": "PH-797804", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 20UM WITH SLS", 
                "description": "Tablet, 6 mg, single dose", 
                "intervention_name": "PH-797804", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 5UM", 
                "description": "Tablet, 6 mg, single dose", 
                "intervention_name": "PH-797804", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PH-797804 PARTICLE SIZE <= 5UM WITH SLS", 
                "description": "Tablet, 6 mg, single dose", 
                "intervention_name": "PH-797804", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 19, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6631040&StudyName=A%20Pharmacokinetic%20Study%20of%20Three%20Different%20Particle%20Sizes%20of%20PH-797804"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Open Label, Single Dose, 6 Treatment, 4-way Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Three Different Particle Sizes of PH-797804 Tablet With and Without the Solubilizing Agent Sodium Lauryl Sulphate (SLS)", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to 72 hours (AUC72)", 
                "measure": "Area Under the Curve From Time Zero to Time 72 hours (AUC72)", 
                "safety_issue": "No", 
                "time_frame": "0,2,3,4,5,6,8,12,24,48,72 hours post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0,2,3,4,5,6,8,12,24,48,72 hours post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0,2,3,4,5,6,8,12,24,48,72 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924650"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}